Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024)

Contineum Therapeutics' Total Non-Current Liabilities history spans 2 years, with the latest figure at $14.8 million for Q4 2024.

  • Quarterly Total Non-Current Liabilities rose 164.32% to $14.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $14.8 million through Dec 2024, up 164.32% year-over-year, with the annual reading at $14.8 million for FY2024, 164.32% up from the prior year.
  • Total Non-Current Liabilities came in at $14.8 million for Q4 2024, up from $5.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $14.8 million in Q4 2024 to a low of $3.9 million in Q2 2024.